FDA Investigating Serious Risk of Malignancy Linked to Zolgensma Gene Therapy (+++)

https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/fda-investigating-serious-risk-malignancy-linked-zolgensma-gene-therapy?utm_medium=email&utm_source=govdelivery 2026 Safety and Availability Communications https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/2026-safety-and-availability-communications OTP Guidance Webinar: Potency Assurance for Cellular and Gene Therapy Products December 10, 2026 Office of Therapeutic Products (OTP) https://www.fda.gov/vaccines-blood-biologics/office-therapeutic-products-otp-events-meetings-and-workshops/otp-guidance-webinar-potency-assurance-cellular-and-gene-therapy-products-12102026?utm_medium=email&utm_source=govdelivery